Journal article
Three decades of glucose-lowering therapy in patients at high cardiovascular risk - A real-world analysis
Diabetes, obesity & metabolism, v 27(2), pp 835-844
Feb 2025
PMID: 39604296
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Over recent years, therapy options and strategies for type 2 diabetes mellitus (T2DM) have developed substantially. This study investigated glucose-lowering treatment in patients with high cardiovascular risk over three decades.
A total of 2158 patients undergoing elective coronary angiography at a tertiary care hospital in Europe were included in three sequential observational studies (OS): OS1 (1999-2000; n = 672), OS2 (2005-2008; n = 1005) and OS3 (2022-2023; n = 481). Sociodemographic data, patient-reported medication, medical histories and blood samples were analysed.
A clear trend towards more complex glucose-lowering therapies was found. A wider array of glucose-lowering drugs was used over time (OS1: 11; OS2: 21; OS3: 25) and the number of different drugs used in combination therapy in a single patient increased to a maximum of five in OS3. Furthermore, substantial differences in applied medication regimens were observed: Sodium-glucose cotransporter-2 inhibitors were the most frequently reported substance class (34.0% of total reported glucose-lowering drugs) in OS3, whilst metformin remained a key component (OS1: 33.9%; OS2: 41.8%; OS3: 32.0%). Other drug classes like sulfonylureas were largely replaced. A total of 69.2% of patients in OS3 achieved an HbA1c level of < 7% (vs. OS1: 51.9%, OS2: 54.7%; p
< 0.001). Over 25% of patients with T2DM were newly diagnosed at admission (OS1: 43.8%, OS2: 29.7%, OS3: 27.2%; p
< 0.001) and had therefore no diabetes-related medication.
These real-world data emphasize a marked shift in T2DM treatment towards novel substance classes. However, the use of incretin mimetics remained low. Significantly more patients reached HbA1c targets in the most recent cohort.
Metrics
1 Record Views
Details
- Title
- Three decades of glucose-lowering therapy in patients at high cardiovascular risk - A real-world analysis
- Creators
- Magdalena Neyer - Private University in the Principality of LiechtensteinJohannes B Vogel - Private University in the Principality of LiechtensteinPascal Elsner - Private University in the Principality of LiechtensteinHeike Kuehrer - Vorarlberg Institute for Vascular Investigation and TreatmentChristoph H Saely - Vorarlberg Institute for Vascular Investigation and TreatmentAxel Muendlein - Vorarlberg Institute for Vascular Investigation and TreatmentAlexander Vonbank - Vorarlberg Institute for Vascular Investigation and TreatmentArthur Mader - Vorarlberg Institute for Vascular Investigation and TreatmentAndreas Festa - Private University in the Principality of LiechtensteinHeinz Drexel - Vorarlberg Institute for Vascular Investigation and TreatmentAndreas Leiherer - Vorarlberg Institute for Vascular Investigation and Treatment
- Publication Details
- Diabetes, obesity & metabolism, v 27(2), pp 835-844
- Publisher
- Wiley
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:001365551900001
- Scopus ID
- 2-s2.0-85210507229
- Other Identifier
- 991022197395704721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- International collaboration
- Web of Science research areas
- Endocrinology & Metabolism